Cargando…
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
AIM OF THE STUDY: Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma (PDAC). The aim of...
Autores principales: | Saukkonen, Kapo, Hagström, Jaana, Mustonen, Harri, Juuti, Anne, Nordling, Stig, Fermér, Christian, Nilsson, Olle, Seppänen, Hanna, Haglund, Caj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459962/ https://www.ncbi.nlm.nih.gov/pubmed/26053486 http://dx.doi.org/10.1371/journal.pone.0129012 |
Ejemplares similares
-
PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma
por: Saukkonen, Kapo, et al.
Publicado: (2016) -
Podocalyxin is a marker of poor prognosis in colorectal cancer
por: Kaprio, Tuomas, et al.
Publicado: (2014) -
Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas
por: Heby, Margareta, et al.
Publicado: (2020) -
Podocalyxin as a Prognostic Marker in Gastric Cancer
por: Laitinen, Alli, et al.
Publicado: (2015) -
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
por: Eurola, Annika, et al.
Publicado: (2021)